ArticleEuropean journal of clinical pharmacology2026
Colistin-induced acute kidney injury in neonates with sepsis and its association with plasma colistin concentration: a prospective cohort study.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColistin is increasingly used as a reserve antibiotic for multidrug-resistant (MDR) Gram-negative infections. However, colistin-induced acute kidney injury (AKI) is under-reported in neonates with sepsis.
objectivesTo evaluate the association and causality between colistin use and AKI in neonatal sepsis, and to explore the correlation between steady-state plasma colistin concentration and AKI development.
methodsIn this prospective cohort study, neonates receiving colistin for proven or probable sepsis were enrolled. Exclusion criteria included major congenital anomalies and death within 72 h of life. Causality of colistin-induced AKI was assessed using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria. Steady-state colistin levels were measured after the sixth dose. AKI was defined and staged according to KDIGO guidelines.
resultsA total of 40 neonates were enrolled (mean gestational age: 29.3 ± 3.1 weeks). The mean duration of colistin therapy was 10.1 ± 0.8 days. AKI occurred in 28/40 (70%), of whom 13 had moderate-to-severe AKI. According to WHO-UMC criteria, 10/28 (35%) AKI cases were classified as “possible” colistin-induced nephrotoxicity. The median (IQR) steady-state colistin concentration was 1.08 (0.53,2.53) mg/L overall. Plasma colistin levels were higher in neonates with “possible” nephrotoxicity (median: 2.09 mg/L) compared with those classified as “unlikely/unclassifiable” (0.95 mg/L) and the non-AKI group (1.04 mg/L) (p = 0.3). Thirteen neonates (33%) died during hospitalization.
conclusionPossible colistin induced AKI was seen in nearly one third cases. Higher steady-state plasma colistin levels was seen in the possible colistin-induced AKI group, highlighting the need for therapeutic drug monitoring and cautious use in this vulnerable population.
Indexed as
Identifiers
41792462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.